AIM: This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT. RESULTS: The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%. CONCLUSION: Eribulin is characterized by a manageable safety profile also when combined with palliative RT.
Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience / Meattini, I., Desideri, I., Di Cataldo, V., Francolini, G., De Luca Cardillo, C., Scotti, V., Loi, M., Detti, B., Mangoni, M., Agresti, B., Baldazzi, V., Greto, D., Casella, D., Bernini, M., Sanchez, L.J., Orzalesi, L., Nori, J., Fambrini, M., Bianchi, S., Livi, L.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 12:9(2016), pp. 1117-1124. [10.2217/fon-2015-0059]
Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience
BERNINI, MARCO;
2016
Abstract
AIM: This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT. RESULTS: The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%. CONCLUSION: Eribulin is characterized by a manageable safety profile also when combined with palliative RT.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Meattini et al 2016 Fut Oncol_eribulin.pdf
Accesso riservato
Dimensione
2.06 MB
Formato
Adobe PDF
|
2.06 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
